Claims
- 1. An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, or a degenerate variant of SEQ ID NO: 1
- 2. The isolated nucleic acid of claim 1 where said nucleotide sequence is a derivative of SEQ ID NO: 1.
- 3. The isolated nucleic acid of claim 1 where said nucleotide sequence is complementary to SEQ ID NO: 1, or complementary to a fragment of SEQ ID NO: 1.
- 4. The isolated nucleic acid of claim 1 where said nucleotide sequence is complementary to a derivative of SEQ ID NO: 1.
- 5. The isolated nucleic acid sequence of claim 1 where said nucleotide sequence is at least 70% identical to the nucleotide sequence of SEQ ID NO: 1, or at least 70% identical to a degenerate variant of SEQ ID NO: 1.
- 6. An isolated nucleic acid sequence comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe the nucleotide sequence of which consists of SEQ ID NO: 1, or a degenerate variant of SEQ ID NO: 1.
- 7. The isolated nucleic acid sequence of claim 6 where the hybridization probe has a nucleotide sequence which consists of a derivative of SEQ ID NO: 1.
- 8. An isolated nucleic acid comprising a sequence that encodes a polypeptide, the amino acid sequence of said polypeptide is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
- 9. The isolated nucleic acid of claim 8 where the amino acid sequence of said polypeptide is selected from the group consisting of SEQ ID NO: 2 with conservative amino acid substitutions, SEQ ID NO: 3 with conservative amino acid substitutions, SEQ ID NO: 4 with conservative amino acid substitutions, SEQ ID NO: 5 with conservative amino acid substitutions, SEQ ID NO: 6 with conservative amino acid substitutions, SEQ ID NO: 7 with conservative amino acid substitutions, SEQ ID NO: 8 with conservative amino acid substitutions, SEQ ID NO: 9 with conservative amino acid substitutions and SEQ ID NO: 10 with conservative amino acid substitutions.
- 10. A purified polypeptide comprising an amino acid sequence, the amino acid sequence of which is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
- 11. The purified polypeptide of claim 10 where said amino acid sequence is at least 70% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
- 12. A purified immunogenic peptide comprising an amino acid sequence of at least 10 consecutive residues, the amino acid sequence of which is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
- 13. A purified polypeptide comprising an amino acid sequence, the amino acid sequence of which is selected from the group consisting of SEQ ID NO: 2 with conservative amino acid substitutions, SEQ ID NO: 3 with conservative amino acid substitutions, SEQ ID NO: 4 with conservative amino acid substitutions, SEQ ID NO: 5 with conservative amino acid substitutions, SEQ ID NO: 6 with conservative amino acid substitutions, SEQ ID NO: 7 with conservative amino acid substitutions, SEQ ID NO: 8 with conservative amino acid substitutions, SEQ ID NO: 9 with conservative amino acid substitutions and SEQ ID NO: 10 with conservative amino acid substitutions
- 14. A purified polypeptide comprising an amino acid sequence, the amino acid sequence of which is selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 21.
- 15. A composition comprising at least one polypeptide according to claim 10 in combination with a pharmaceutically acceptable carrier.
- 16. A composition comprising at least one polypeptide according to claim 12 in combination with a pharmaceutically acceptable carrier.
- 17. An antibody capable of binding to the polypeptide of claim 10.
- 18. An antibody capable of binding to the polypeptide of claim 14.
- 19. A kit for the detecting the presence of a virus of the SIVcpz type in a sample, said kit comprising an antibody according to claim 17 and reagents for the detection of the immunological complex formed between said antibody and said virus.
- 20. The kit of claim 19 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 21. The kit of claim 19 where said kit comprises an antibody according to claim 18.
- 22. The kit of claim 21 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 23. A method of detecting the presence of a virus of the SIVcpz type in a biological sample containing an antigen said virus comprising contacting the sample with the antibody of claim 14 under conditions that allow the formation of an antibody-antigen complex and detecting said complex.
- 24. The method of claim 23 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 25. The method of claim 23 where the antibody is the antibody of claim 15.
- 26. The method of claim 25 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 27. A method of detecting the presence of a virus of the SIVcpz type in a biological sample comprising contacting said sample with the nucleic acid of claim 1 and detecting said nucleic acid bound to the genomic DNA, mRNA or cDNA of the SIVcpz virus.
- 28. The method of claim 27 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 29. A method of detecting the presence of a virus of the SIVcpz type in a biological sample comprising contacting said sample with the nucleic acid of claim 2 and detecting said nucleic acid bound to the genomic DNA, mRNA or cDNA of the SIVcpz virus.
- 30. The method of claim 29 where the virus is selected from the group consisting of SIVcpzTAN1, SIVcpzTAN2 and SIVcpzANT.
- 31. A vector comprising the nucleic acid of claim 1.
- 32. A vector comprising the nucleic acid of claim 2.
- 33. A cell comprising the vector of claim 31.
- 34. A cell comprising the vector of claim 32.
Parent Case Info
[0001] This application claims priority to and benefit of provisional application No. 60/349,617, filed Jan. 17, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60349617 |
Jan 2002 |
US |